Q BioMed Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Q BioMed Inc. (QBIO) is a biomedical acceleration and development company that licenses, acquires, and provides resources to life sciences and healthcare firms targeting clinical-stage and near-revenue biomedical assets across oncology, rare diseases, vascular conditions, and ophthalmology. The company offers Strontium Chloride Sr-89 (also branded as Metastron and Strontium89), an FDA-approved radiopharmaceutical injection for treating pain from metastatic bone cancer in patients with cancers such as breast, prostate, and lung; it develops QBM-001, an oral therapy for rare pediatric non-verbal autism spectrum disorder; Uttroside-B, a novel chemotherapeutic agent for liver cancer; and MAN-01 (or Man-01), a small-molecule eye drop for primary open-angle glaucoma. Q BioMed operates primarily in the United States with distribution efforts extending to Canada and China, serving healthcare providers, hospitals, veterans affairs systems, and patients with unmet needs in these therapeutic areas; it was founded in 2013 (formerly ISMO Tech Solutions, Inc., renamed in July 2015) and is headquartered at 366 Madison Avenue, 3rd Floor, New York, New York. Recent developments include a partnership with EVERSANA to accelerate commercialization of Strontium89 through integrated market access, analytics, pharmacovigilance, and distribution targeting U.S. Veterans Affairs and Department of Defense sectors; conversion of future royalties into a 15% equity stake in Mannin Research Inc., adding multi-million-dollar asset value and $20 million in additional royalties tied to therapies for acute respiratory distress syndrome, glaucoma, and kidney disease; and expansion of Strontium89 sales with a $500,000 order in China alongside strengthened intellectual property for its liver cancer portfolio.
Q Biomed (OTCMKTS:QBIO) vs. GeneDx (NASDAQ:WGS) Financial Comparison
Establishment Labs (NASDAQ:ESTA) & Q Biomed (OTCMKTS:QBIO) Critical Contrast
Q Biomed (OTCMKTS:QBIO) & Auna (NYSE:AUNA) Head to Head Review
Q Biomed (OTCMKTS:QBIO) & GoodRx (NASDAQ:GDRX) Financial Survey
SBC Medical Group (NASDAQ:SBC) and Q Biomed (OTCMKTS:QBIO) Head-To-Head Contrast
Q BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder value
Q BioMed gets notice of allowable US patent for liver cancer treatment Uttroside B
Q BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Research
Q Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatment
Q BioMed reports Strontium89 sales revenue surge in shareholder update
Q BioMed says new publication shows superior safety and efficacy of Uttroside-B versus FDA approved drug Sorafenib
Q BioMed says its strategy is paying off as it outlines its value proposition in multibillion-dollar markets
Q BioMed announces publication of research supporting efficacy and development of its Uttroside-B chemotherapeutic to treat liver cancer
Q BioMed outlines strategic direction and goals for 2022
Q BioMed says it is seeing a ‘significant uptrend' in revenues as it continues to roll out Strontium89
Q BioMed bolsters commercialization of Strontium89 with EVERSANA partnership
Q BioMed raises $2M with plans for uplisting on NASDAQ; updates on activity for coming months
Q BioMed raises $2M with plans for uplisting on NASDAQ, shares plans for upcoming months
Q BioMed sees uptick in 4Q sales of Strontium89 amid commercial rollout
Q BioMed Inc. Provides Update on Strontium89 Commercial Roll Out Revenue Up in 4th Quarter with Positive Trend